Today: 9 June 2026
Rio Tinto stock drops as metals rout bites; Glencore clock and Brazil deal loom
31 January 2026
2 mins read

Rio Tinto stock drops as metals rout bites; Glencore clock and Brazil deal loom

NEW YORK, Jan 31, 2026, 06:06 EST — Market closed

  • On Friday, Rio Tinto’s shares listed in the U.S. dropped roughly 4.3%.
  • Gold, silver, and copper took a sharp hit, intensifying the sell-off in mining stocks.
  • Investors enter a week marked by takeover-code filings and several important upcoming dates.

Shares of Rio Tinto slipped on Friday, with the miner’s U.S.-listed stock last seen at $91.03. That’s down $4.05, or roughly 4.3%, from the previous session’s close, according to market data.

Metals prices took a sharp turn lower heading into month-end. “The market thinks Kevin Warsh is rational and that he won’t push aggressively for rate cuts,” Tom Price noted, highlighting profit-taking after a crowded rally. Ole Hansen labeled the recent surge in gold and silver as “highly speculative,” while Ross Norman remarked that “precious metals have discovered gravity.” Reuters

Why it matters for Rio now: the company is stepping into a tangle of catalysts. Late Thursday, Rio and Aluminium Corporation of China (Chinalco) struck a deal to acquire control of Companhia Brasileira de Aluminio (CBA) for 4.69 billion reais ($903.61 million). The partners plan to launch a tender offer for the remaining shares, in line with local regulations. “I like it, it’s a very bullish signal,” said Baden Moore, highlighting how the deal aligns with Rio’s push into low-carbon aluminium. He also pointed out Rio is expected to announce a potential tie-up with Glencore by Feb. 5. Reuters

Rio Tinto shares closed Friday in London down 1.62% at 67.38 pounds, underperforming the stronger FTSE 100. The stock ended roughly 4% below its 52-week peak reached just a day before, with trading volume surpassing its recent average, MarketWatch reported.

Deal chatter has pulled takeover-rule details back into focus. A Form 8.3 filing from State Street Global Advisors & Affiliates, dated Jan. 30, revealed holdings of roughly 2.2% in Rio Tinto plc shares and about 7.5% in Rio Tinto Limited stock. The firm also flagged disclosures related to Glencore. (For context, a Form 8.3 is a UK Takeover Code filing required when investors hold 1% or more during an “offer period.”) investegate.co.uk

U.S. markets are closed for the weekend, leaving Rio’s early Monday session to hinge on macro factors: the dollar’s direction and copper futures following Friday’s reversal. Expect thin liquidity through mid-February, which could exaggerate price swings.

Rio remains fundamentally a commodities beta play. Iron ore drives its cash flow, while copper is closely watched as the company shifts toward “future-facing” metals, taking on heavyweights like BHP and Vale in the process.

The Brazil aluminium deal is a minor blip on Rio’s balance sheet, yet it introduces another angle investors are watching closely: capital discipline, portfolio adjustments, and just how aggressively management aims to prepare for lower-carbon supply chains.

The risk is straightforward and harsh. Should the metal pullback deepen—fueled by a stronger dollar or weaker demand cues from China—miners could face a double blow: falling commodity prices and a drop in risk appetite simultaneously.

The schedule is packed. A “Notice to ASX/LSE” from Jan. 8 pins Rio’s 2025 full-year results release on Feb. 19. The final dividend ex-dividend date for ordinary shares falls on March 5—that’s the first day shares trade without the upcoming dividend entitlement.

Traders are zeroing in on two key dates: Feb. 5, when any Glencore-related news could drop, and Feb. 19, when Rio reports annual results and announces dividends. Monday’s open will reveal if the metals selloff from Friday has more room to run.

Stock Market Today

  • IREN Stock Nears $60 on AI Data-Center Expansion, Bitcoin Rebound
    June 9, 2026, 9:55 AM EDT. IREN Limited shares rose 8.9% to $59.19 on Monday, nearing $60 ahead of Tuesday's Nasdaq open amid a bitcoin rebound and a strategic pivot to AI cloud infrastructure. The stock, known for volatility, reflects uncertainty whether it will trade more like a bitcoin miner or an AI cloud operator. IREN plans an 800-megawatt data-center campus in South Australia, supported by clean energy, targeting 2028 energisation and generating substantial jobs. The firm recently secured a $3.4 billion, five-year AI cloud contract with Nvidia and maintains $3.1 billion in annualized run-rate revenue from existing contracts. Despite these developments, risks remain from bitcoin price swings, funding requirements, and data-center construction delays.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut
Previous Story

First U.S. bank failure of 2026: What happened after Metropolitan Capital Bank & Trust was shut

Gold price set for a bumpy week after historic slide from record highs
Next Story

Gold price set for a bumpy week after historic slide from record highs

Go toTop